Table 1.

Summary of agreement between PD-L1 IHC 22C3 and 28-8 assays

	All biopsies (n=1930) n (%)	Biopsies with a confirmed lung cancer diagnosis (n=412) n (%)
PD-L1 IHC difference 0%–10%	1825 (94.6)	393 (95.4)
PD-L1 IHC difference 11%–20%	60 (3.1)	10 (0.5)
PD-L1 IHC difference >20%	45 (2.3)	9 (2.2)
PD-L1 IHC difference 22C3=28-8	1589 (82.3)	340 (82.5)
PD-L1 IHC difference 22C3<28-8	132 (6.8)	27 (6.6)
PD-L1 IHC difference 22C3>28-8	209 (10.8)	45 (10.9)

IHC, immunohistochemistry; PD-L1, programmed death ligand 1.